Surgery, radiation, and cytotoxic/targeted therapies are common treatment approaches in most advanced cancers.1 However, global mortality remains high for many patients with advanced tumours.2 The goal of Immuno-Oncology (I-O) research is to fulfill the unmet need for improving clinical outcomes in several advanced cancers.
The Potential of I-O Drives Research Efforts at BMS
Immuno-Oncology (I-O) is a rapidly evolving field that focuses on the immune system in the fight against cancer.1 At BMS, we are dedicated to finding new ways to stop cancer from evading the immune system, thereby restoring the body's natural ability to recognise and eliminate cancer.3,4 Because of our ongoing commitment, this site will be continually updated with the latest facts, news, and developments in Immuno-Oncology.
- Devita VT Jr, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366:2207-2214.
- International Agency for Research on Cancer. GLOBOCAN 2012. Fact Sheets. http://globocan.iarc.fr/Default.aspx. Accessed September 2, 2014.
- Borghaei H, Smith MR, Campbell KS. NIH Public Access Manuscript. Immunotherapy of cancer.Eur J Pharmacol. 2009;625(1-3):41-54. doi:10.1016/j.ejphar.2009.09.067.
- Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(suppl 8):viii6-viii9.